The executive joined McGill and Partners in 2019 but stood down at the end of 2022, having been diagnosed with motor neurone disease.
Fillingham
The executive joined McGill and Partners in 2019 but stood down at the end of 2022, having been diagnosed with motor neurone disease.
Fillingham